Compare · ARVN vs KYMR

ARVN vs KYMR

Side-by-side comparison of Arvinas Inc. (ARVN) and Kymera Therapeutics Inc. (KYMR): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both companies sit in the Health Care sector. ARVN focuses on Biotechnology: Pharmaceutical Preparations, while KYMR focuses on Biotechnology: Biological Products (No Diagnostic Substances).
  • KYMR is the larger of the two at $9.84B, about 23.3x ARVN ($423.0M).
  • ARVN has been more active in the news (9 items in the past 4 weeks vs 2 for KYMR).
  • Both have 25 recent analyst ratings on file.
MetricARVNKYMR
Company
Arvinas Inc.
Kymera Therapeutics Inc.
Price
-
-
Market cap
$423.0M
$9.84B
1M return
-
+3.84%
1Y return
-
+75.65%
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Biological Products (No Diagnostic Substances)
Exchange
NASDAQ
NASDAQ
IPO
2018
2020
News (4w)
9
2
Recent ratings
25
25
ARVN

Arvinas Inc.

Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Bayer AG, and Insilico Medicine, Inc. Arvinas, Inc. was incorporated in 2013 and is based in New Haven, Connecticut.

KYMR

Kymera Therapeutics Inc.

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; and STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases. The company was founded in 2015 and is headquartered in Watertown, Massachusetts.

Latest ARVN

Latest KYMR